Pharmaceuticals and Biotechnology company Hester Biosciences announced Q3FY22 results: Domestic sales have registered a growth of 3% in Q3 FY22, and 24% in 9M FY22. Exports have increased by 88% in Q3 FY22 and 14% in 9M FY22. Overall, the sales grew by 2% in Q3 FY22, and 16% in 9M FY22, as compared to the corresponding period(s). The revenue during the corresponding previous quarter (Q3 FY21) included a one-time license fee and services of Rs 33.12 million against which there is no income in the current year. This has an impact of 6% on margins during that period. Overall, the sales of vaccines have remained the same in Q3 FY22, but have registered a growth of 16% in 9M FY22. Last year around Q2, Q3, and Q4, there were major disease outbreaks in the poultry industry which led to a spurt in the demand for poultry vaccines. While our vaccines kept the poultry industry immunised from the disease in the last financial year, the overall poultry health situation has been better this year, thereby registering a normal growth. The sales of health products have registered a growth of 42% in Q3 FY22 and 49% in 9M FY22. Result PDF
Hester Biosciences Limited Q2 and H1 FY22 Financial Highlights: Revenue up by 6% and 24%, for Q2 and H1 FY22 Net Profit up by 16% and 35%, for Q2 and H1 FY22 Sales for Q2 FY22 and Q1 FY22 grew by 6% and 50% with overall H1 FY22 being higher by 24% as compared to corresponding periods. Overall, the sales of vaccines have registered a growth of 13% in Q2 FY22 and 26% in H1 FY22, and the sales of Health Products have registered a growth of 31% in Q2 FY22 and 53% in H1 FY22. Domestic sales have registered a growth of 21% in Q2 FY22 and 38% in H1FY22. There is marginal decrease in export sales in Q2 and H1 FY22. Export orders are affected due to restricted cargo movements globally. Result PDF